Veracyte plans to launch a new version of its Percepta test and present data for a nasal swab lung cancer diagnostic this year.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
As part of the collaboration, Johnson & Johnson will build a lung cancer center at Boston University and build upon programs linked to cancer research.
The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.
The firm’s emphasis on automation has yielded Dx products for blood banks, assays for HIV and acute kidney injury, and flexible diagnostic test systems that can adapt to labs’ changing needs.
The companies will work to develop an affordable, portable, and easy-to-use HIV quantitative viral load test using Cue's Lab-In-A-Box MDx platform.
Johnson & Johnson announced that it would be cutting about 3,000 jobs from its medical devices section.
Using J&J's CellSearch platform, researchers have demonstrated the expression of PD-L1 on CTCs, a finding they believe they are the first to show.
Three new assays were presented in posters at April's Clinical Virology Symposium.
The long-running Framingham Heart Study has received a $38 million grant, according to the Boston Globe.
A Stanford University investigation finds that its researchers did not take part in He Jiankui's work to develop gene-edited infants.
Retraction Watch reports that two researchers had both a Science and a Nature paper retracted last week.
In Genome Biology this week: genomic sequencing of milkweed bug, benchmark comparison of single-cell RNA sequencing platforms, and more.